

## 2/12/82 PERTUSSIS VACCINE SYMPOSIUM

Dr. Schuh - Connaught Laboratories, Canada

I would like to make a short comment on the issue of compromising between the price and purity because I am from the company which produces vaccines, so we are, of course, very interested, first of all, with the price. And we followed similar reasoning as Dr. Nagel's here, that everybody who is a producer -- throwing out 90 percent of activity and keeping ten at the first stage of purification.

We adopted for this reason as a preliminary approach the purification system which has relatively large yields of protectivity measured in the mouse test, something between 30 and 40 percent of the original bacterial content of protectivity. It may be on the lower end of the purification stage because it extracts something around 40 percent of the bacterial protein. The advantage might be that it contains not only the LPF but it contains probably also other components of the protective complex, being perhaps that also other antigens -- we didn't test them yet but we intend to do so. So that is what we think might be also one of the approaches. (page II-55 - II-56)

